Arcturus Receives FDA Approval of Phase 2 Vaccine Trials
BIOTECH: Company Moves Forward on One Shot mRNA COVID-19 Vaccine
“If a single shot vaccine is desired, our view is that you need a technology that invokes not only humoral immunity, but cellular immunity is also very important.” JOE PAYNE
▪ By NATALLIE ROCHA
Arcturus Therapeutics (Nasdaq: ARCT) received approval from the Food and Drug Administration (FDA) to proceed with Phase 2 trials of its COVID-19 vaccine candidate, LUNAR-COV19.
The Jan. 4 announcement comes a week after the local biotech company...
Read latest San Diego Business Journal online.